相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases
S. Miuma et al.
TRANSPLANTATION PROCEEDINGS (2018)
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY (2017)
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b
Eiichi Ogawa et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study
E. B. Tapper et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients With Hepatitis C: Results From the HCV-TARGET Study
Varun Saxena et al.
HEPATOLOGY (2017)
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease
K. Rajender Reddy et al.
HEPATOLOGY RESEARCH (2017)
Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis
Michelle T. Martin et al.
TRANSPLANTATION (2017)
Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection
Shelby Corman et al.
VALUE IN HEALTH (2017)
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
Annette Bruchfeld et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation
Yoshihide Ueda et al.
TRANSPLANT INTERNATIONAL (2016)
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
Norah A. Terrault et al.
GASTROENTEROLOGY (2016)
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence
Fred Poordad et al.
HEPATOLOGY (2016)
Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals
Jagpreet Chhatwal et al.
HEPATOLOGY (2016)
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
Jan Sperl et al.
JOURNAL OF HEPATOLOGY (2016)
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies
M. Mizokami et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns et al.
LANCET INFECTIOUS DISEASES (2016)
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis
P. A. Cortesi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?
Andrew J. Muir et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy
Jun Itakura et al.
HEPATOLOGY RESEARCH (2015)
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Eric Lawitz et al.
LANCET (2015)
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
David Roth et al.
LANCET (2015)
Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy
Yasuhiro Kamo et al.
HEPATOLOGY RESEARCH (2015)
Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: A Flood of Opportunity''
E. J. Gane et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Management of the Transplant Recipient with Chronic Hepatitis C
James R. Burton et al.
CLINICS IN LIVER DISEASE (2013)
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir and Asunaprevir
Fiona McPhee et al.
HEPATOLOGY (2013)
Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin
Yvon Calmus et al.
JOURNAL OF HEPATOLOGY (2012)
Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients
Andrew Aronsohn et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2009)
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection
B. J. Veldt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
Marina Berenguer
JOURNAL OF HEPATOLOGY (2008)
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients
M Berenguer et al.
HEPATOLOGY (2002)
HCV-related fibrosis progression following liver transplantation:: increase in recent years
M Berenguer et al.
JOURNAL OF HEPATOLOGY (2000)
分享论文
